Tango Therapeutics, a Cambridge, Mass-based biotech company discovering next-gen precision cancer medicines, is merging with BCTG Acquisition Corp, a special purpose acquisition company (SPAC) sponsored by Boxer Capital.
Upon closing of the transaction, the company will be named Tango Therapeutics, Inc. and will be led by Barbara Weber, President and CEO of Tango.
The deal creates a publicly listed precision medicine company focussed on developing next-gen targeted cancer therapies.
“This morning’s announcement is a key milestone for Tango as it ensures we have access to the capital needed to advance our preclinical programs and initiate clinical studies of our three lead programs, as we continue our mission of bringing transformational therapies to patients” said Dr. Weber.
Proceeds from the transaction are expected to provide Tango with the capital needed to further develop its pipeline.